Pharmaceuticals

Biomarkers Market Growth Opportunities: Insights from 2025–2029

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Biomarkers Market Expected To Expand Between 2025 And 2029?

The biomarkers market has observed substantial growth recently. It is set to expand from $68.77 billion in 2024 to $77.42 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.6%. This growth experienced in prior periods can be attributed to several factors including advancements in genomics and proteomics technologies, a rise in the prevalence of chronic diseases, an increasing emphasis on personalized medicine, a growing demand for companion diagnostics, and the expansion of applications within drug development.

The biomarkers market is projected to experience swift expansion in the coming years, anticipated to reach $131.78 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.2%. Several factors contribute to this growth during the forecast period, including an increased emphasis on early disease identification and prevention, the broader application of biomarkers in oncology and immunotherapy, greater investment in precision medicine initiatives, the emergence of liquid biopsy as a non-invasive technique for biomarker detection, and a rising inclination towards biomarkers in drug discovery and development. Key trends expected during this period encompass the creation of multi-biomarker panels, the rise of exosome-based biomarkers, the uptake of point-of-care biomarker testing, the incorporation of real-world data into biomarker research, and the investigation of microbiome-based biomarkers.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp

What Are The Main Drivers Boosting The Biomarkers Industry’s Expansion?

The rising incidence of heart diseases is anticipated to propel the biomarkers market’s growth throughout the forecasted period. The application of biomarkers in managing patients with heart conditions has seen a significant increase over recent years. Currently, natriuretic peptides are the most commonly used biomarker, aiding in the diagnosis of heart failure patients. Furthermore, biomarkers such as circulating biomarkers with high sensitivity C-reactive protein are utilized for diagnosing heart failure. Heart disease is a leading cause of death for people across most racial and ethnic groups in the United States, and this increase in heart diseases will drive the demand for biomarkers. For instance, in August 2022, a report published by the American College of Cardiology, a US-based non-profit medical association, indicated that all four cardiovascular risk factors are expected to rise in the United States between 2025 and 2060. The largest percentage increase is projected for diabetes, with a 39.3% rise to 55 million individuals, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The researchers also observed that the most substantial projected increases in cardiovascular disease rates were for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), followed by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). Due to the growing prevalence of heart diseases and associated fatalities, an expansion in the biomarkers market is expected.

What Are The Major Segment Categories Driving The Biomarkers Market Growth?

The biomarkers market covered in this report is segmented –

1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers

2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases

3) By Type: Biomarker Of Exposure, Biomarker Of Diseases

4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies

Subsegments:

1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers

2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers

3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers

How Are Emerging Market Trends Shaping The Biomarkers Industry Landscape?

Leading companies within the biomarker market are concentrating on devising innovative solutions, like a novel biological marker, to foster innovation through cooperative research, the assimilation of technology, and thorough clinical validation. A novel biological marker represents a recently discovered indicator that mirrors biological processes and assists in the diagnosis or monitoring of diseases. It can manifest as a molecule, a gene, or a cellular trait with significant implications for personalized medicine. For instance, in September 2024, Genialis, a US-based company specializing in computational precision medicine, introduced a pioneering biomarker. This first-in-class biomarker elevates the accuracy of predictions regarding patient responses to KRAS inhibitors, thereby enabling individualized treatment strategies and enhancing clinical outcomes. Its extensive utility across diverse cancer types aids in efficient drug development and refines patient selection for targeted therapies.

Who Are The Top Performing Companies In The Biomarkers Market In Recent Years?

Major companies operating in the biomarkers market include Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Which Regional Markets Are Contributing Most To The Biomarkers Industry Expansion?

North America was the largest region in the biomarkers market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/customise?id=6485&type=smp

Browse Through More Reports Similar to the Global Biomarkers Market 2025, By The Business Research Company

Small Animal Imaging In Vivo Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/small-animal-imaging-in-vivo-global-market-report

Renal Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Biologics Market 2025

https://www.thebusinessresearchcompany.com/report/biologics-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795